Patient no. | No. of metastases | Observed survival (d) | Predicted survival* (d) |
---|---|---|---|
1 | 1 | 135 | 212 |
2 | 1 | 181 | 175 |
3 | 2 | 191 | 168–181 |
4 | 1 | 197 | 248 |
5 | 3 | 202 | 149–207 |
6 | 5 | 202 | 250–304 |
7 | 1 | 204 | 362 |
8 | 2 | 227 | 241–471 |
9 | 2 | 253 | 240–381 |
10 | 2 | 290 | 201–233 |
11 | 1 | 353 | 427 |
12 | 1 | 381 | 471 |
13 | 2 | 401 | 338–439 |
14 | 2 | 466 | 358–521 |
15 | 2 | 477 | 471–472 |
16 | 1 | 484 | 507 |
17 | 1 | 577 | 412 |
18 | 2 | 701 | 344–577 |
19 | 2 | 712 | 531–720 |
20 | 2 | 801 | 704–869 |
↵* For first and third MS.
Predicted survival is based on the kinetic data of the first (k3, k4, VB, FD) and third (k1, k2, k4, VB) MS according to Table 6. In patients with more than one metastatic lesion, we used a range of time for the predicted survival.